Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 04:00PM ET
2.85
Dollar change
+0.14
Percentage change
5.17
%
Index- P/E- EPS (ttm)-1.59 Insider Own46.29% Shs Outstand26.29M Perf Week-2.73%
Market Cap74.93M Forward P/E- EPS next Y-2.06 Insider Trans0.00% Shs Float14.12M Perf Month-12.31%
Income-41.97M PEG- EPS next Q-0.22 Inst Own15.11% Short Float1.50% Perf Quarter86.27%
Sales6.77M P/S11.07 EPS this Y4.94% Inst Trans-2.70% Short Ratio0.12 Perf Half Y103.57%
Book/sh1.95 P/B1.46 EPS next Y-37.86% ROA-34.25% Short Interest0.21M Perf Year74.85%
Cash/sh3.64 P/C0.78 EPS next 5Y- ROE-61.18% 52W Range1.13 - 6.47 Perf YTD80.38%
Dividend Est.- P/FCF- EPS past 5Y86.55% ROI-81.08% 52W High-55.95% Beta0.72
Dividend TTM- Quick Ratio6.62 Sales past 5Y61.16% Gross Margin53.18% 52W Low151.99% ATR (14)0.36
Dividend Ex-Date- Current Ratio6.62 EPS Y/Y TTM99.98% Oper. Margin-638.99% RSI (14)48.17 Volatility7.31% 12.16%
Employees37 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin-620.09% Recom1.00 Target Price7.25
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q57.45% Payout- Rel Volume0.05 Prev Close2.71
Sales Surprise- EPS Surprise45.45% Sales Q/Q-86.63% EarningsMar 20 BMO Avg Volume1.82M Price2.85
SMA20-10.41% SMA505.76% SMA20050.77% Trades Volume87,673 Change5.17%
Date Action Analyst Rating Change Price Target Change
Oct-25-22Initiated H.C. Wainwright Buy $9
Apr-19-21Initiated SVB Leerink Outperform $26
Apr-19-21Initiated JP Morgan Overweight $22
Apr-19-21Initiated Jefferies Buy $23
Mar-20-24 12:52PM
07:00AM
Mar-05-24 08:30AM
07:30AM
Jan-25-24 07:00AM
07:00AM Loading…
Nov-16-23 07:00AM
Sep-06-23 07:11AM
Aug-22-23 07:00AM
Aug-14-23 07:00AM
Jun-14-23 09:00AM
Jun-08-23 07:00AM
Jun-01-23 04:20PM
08:09AM
May-30-23 05:28PM
Apr-11-23 07:00AM
08:05AM Loading…
Mar-09-23 08:05AM
Feb-16-23 07:00AM
Feb-09-23 07:00AM
Feb-06-23 07:00AM
Jan-23-23 07:00AM
Jan-06-23 01:07PM
Jan-03-23 07:00AM
Dec-10-22 10:00AM
Nov-16-22 04:05PM
Nov-03-22 04:05PM
09:00AM
Nov-01-22 07:00AM
Oct-07-22 11:00AM
Sep-26-22 08:00AM
Sep-13-22 04:05PM
07:41AM Loading…
Sep-07-22 07:41AM
Jun-16-22 04:05PM
Jun-15-22 07:00AM
Jun-02-22 07:00AM
Jun-01-22 07:00AM
May-31-22 04:05PM
May-17-22 07:00AM
May-12-22 07:00AM
May-05-22 03:44PM
07:00AM
Apr-27-22 10:05AM
Mar-24-22 06:30AM
Mar-22-22 05:20PM
Mar-10-22 06:30AM
Mar-07-22 08:35AM
Feb-01-22 06:30AM
Jan-28-22 07:00AM
Jan-18-22 08:30AM
Dec-20-21 10:06AM
07:00AM
Nov-15-21 07:00AM
Nov-11-21 12:16PM
10:08AM
Nov-09-21 06:30AM
Nov-04-21 07:00AM
Nov-02-21 07:00AM
Oct-15-21 07:00AM
Oct-07-21 12:36PM
11:31AM
Sep-23-21 10:26AM
Aug-16-21 07:05AM
Jul-27-21 08:00AM
Jul-13-21 07:00AM
May-25-21 06:30AM
May-20-21 06:30AM
May-18-21 06:30AM
May-10-21 09:29AM
Apr-01-21 07:54AM
Mar-25-21 11:31AM
Mar-24-21 08:55PM
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.